B3.040 - Blood Cell Dyscrasias Flashcards
Blood Diagnostic findings of ET
marked thrombocytosis with abnormal morphology; circulating megakryocytic fragments
mastocytosis bone marrow findings
aggregates of mast cells positive for metachromatic stains
what mutation is associated with myeloproliferative neoplasms
mutuation constituitively activated tyrosine kinase
CML is a neoplasm of what
pluripotential hematopoietic stem cell
imatinib aka
gleevec
clinical features of PMF
non specific symptoms - fatigue, malaise, weight loss splenomegaly, often massive infections, hemorrhage
Blood Diagnostic findings of CML
leukocytosis >20,000 all stages of maturation basophilia
PMF is neoplasm of what
multipotential hematopoietic stem cell with reactive fibrosis
Myeloid neoplasms
myeloproliferative neoplasms acute myeloid leukemia myelodysplastic syndromes
clinical features of CML
initially asymptomatic fatigue, malaise, fever, weight loss splenomegaly thrombosis or bleeding
Blood Diagnostic findings of PMF
leukoerythroblastosis Prominent anisopoikilocytosis with tear drop shaped RBCs
what mutation is associated with PV and up to 50% of cases of PMF/ET
JAK2
PMF has what factors
profibrotic growth factors (PDGF, TGFbeta) from megakryocytes
Blood diagnostic findings of PV
elevated RBC Low or normal serum erythropoietin
what is a diagnostic hallmark of CML
BCR/ABL fusion gene
PV features markedly increased what
total body erythrocyte mass
what is distinctive of ET
markedly increased platelets and abnormal platelet function
What is ET a neoplasm of
multipotential hematopoietic stem cell with uncontrolled proliferation of megakaryocytes
what does the JAK2 mutation do
promotes cytokine independent growth as well as hypersensitivity to growth fators
PV clinical features
increased RBC mass - plethora, headache, dizziness, visual disturbances, angina, intermittent claudation splenomegaly, thrombosis or bleeding
what neoplasm is associated with the granulocytic pathway
CML
mastocytosis is noplasm of
mast cells
is JAK2 mutation specific to a disease?
no
what drug targets the JAK2 mutation
ruxolitinib